Ardakani, K.Y.; Pepe, F.F.; Capici, S.; Clementi, T.D.; Cazzaniga, M.E.
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Curr. Oncol. 2025, 32, 387.
https://doi.org/10.3390/curroncol32070387
AMA Style
Ardakani KY, Pepe FF, Capici S, Clementi TD, Cazzaniga ME.
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Current Oncology. 2025; 32(7):387.
https://doi.org/10.3390/curroncol32070387
Chicago/Turabian Style
Ardakani, Khashayar Yazdanpanah, Francesca Fulvia Pepe, Serena Capici, Thoma Dario Clementi, and Marina Elena Cazzaniga.
2025. "Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)" Current Oncology 32, no. 7: 387.
https://doi.org/10.3390/curroncol32070387
APA Style
Ardakani, K. Y., Pepe, F. F., Capici, S., Clementi, T. D., & Cazzaniga, M. E.
(2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). Current Oncology, 32(7), 387.
https://doi.org/10.3390/curroncol32070387
